Food Allergy In The First 15 Year Of Life: Wave 5 Of The HealthNuts Longitudinal Study
Funder
National Health and Medical Research Council
Funding Amount
$2,435,075.00
Summary
Understanding why some food allergy persists into adolescence is critical because adolescents are at highest risk of life-threatening allergic reactions. Food allergy also has lifelong impacts on children's health. HealthNuts is a longitudinal study of 5300 children that measured allergic diseases from infancy. At the age 15 follow-up, we will identify predictors of food allergy persistence and severity, and the consequences of infant food allergy on later respiratory health.
Providing Translatable Evidence To Advance Prevention And Management Of COPD: A Longitudinal Study From The 1st To 7th Decade Of Life
Funder
National Health and Medical Research Council
Funding Amount
$2,893,320.00
Summary
Chronic obstructive pulmonary disease (COPD) makes breathing difficult and reduces wellbeing. People are more likely to get COPD from the age of 60 years, but we do not know why and who. Our study will develop tools to identify early who will develop COPD by 60 years. We will also develop a tool to identify 60-year-old individuals whose lung function is declining faster than normal. These findings will help us to better prevent and manage COPD.
Prospective Ovarian Cancer Cohort To Authenticate Stratification Of Prognosis In Ovarian Tumours (POCCA-SPOT)
Funder
National Health and Medical Research Council
Funding Amount
$993,580.00
Summary
Ovarian cancer has poor survival, with less than 40% of women surviving 5 years. There is a wide range of survival, but very few characteristics that indicate which patients will do well or poorly. We have developed a tumour test at diagnosis, that can predict prognosis at 5 years. In newly diagnosed cases, we will test tumours to predict prognosis and then determine the accuracy and assess patient acceptability. This study will lead to clinical use of the test and improve treatment decisions.
Cancers can spread to the lung causing fluid build-up and requires drainages in hospital that are painful and costly. Surgery is previously seen as the definitive option to stop fluid forming, but is invasive with complications. Indwelling pleural catheter (IPC) is a novel implanted device inside the chest that allows patients to drain fluid at home. AMPLE Trial-3 is the first multicenter randomized clinical trial to compare surgery vs IPC to provide fluid control and improve quality of life.
Whole-of-population CRISPR Point-of-care Testing For Congenital Cytomegalovirus To Prevent Hearing And Neurodevelopment Disabilities Through A Public Health Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,058,920.00
Summary
Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.